Synergy Asset Management LLC Invests $75,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

Synergy Asset Management LLC acquired a new stake in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) during the 4th quarter, Holdings Channel reports. The fund acquired 2,500 shares of the biopharmaceutical company’s stock, valued at approximately $75,000.

A number of other hedge funds have also recently bought and sold shares of the company. The Manufacturers Life Insurance Company grew its position in shares of TG Therapeutics by 3.7% in the second quarter. The Manufacturers Life Insurance Company now owns 80,664 shares of the biopharmaceutical company’s stock valued at $1,435,000 after purchasing an additional 2,871 shares during the period. Creative Planning boosted its stake in TG Therapeutics by 34.7% in the 2nd quarter. Creative Planning now owns 46,839 shares of the biopharmaceutical company’s stock worth $833,000 after buying an additional 12,076 shares during the last quarter. SG Americas Securities LLC grew its holdings in TG Therapeutics by 181.9% in the 3rd quarter. SG Americas Securities LLC now owns 23,614 shares of the biopharmaceutical company’s stock valued at $552,000 after buying an additional 15,238 shares during the period. Handelsbanken Fonder AB increased its stake in shares of TG Therapeutics by 22.6% during the 3rd quarter. Handelsbanken Fonder AB now owns 49,900 shares of the biopharmaceutical company’s stock valued at $1,167,000 after acquiring an additional 9,200 shares during the last quarter. Finally, Daymark Wealth Partners LLC lifted its holdings in shares of TG Therapeutics by 73.7% during the 3rd quarter. Daymark Wealth Partners LLC now owns 40,811 shares of the biopharmaceutical company’s stock worth $955,000 after acquiring an additional 17,311 shares during the period. Institutional investors and hedge funds own 58.58% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on TGTX. The Goldman Sachs Group boosted their target price on shares of TG Therapeutics from $20.00 to $22.00 and gave the company a “neutral” rating in a report on Tuesday, November 5th. StockNews.com raised TG Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 7th. TD Cowen assumed coverage on TG Therapeutics in a report on Tuesday, October 29th. They issued a “buy” rating and a $50.00 target price on the stock. JPMorgan Chase & Co. upped their price target on TG Therapeutics from $30.00 to $43.00 and gave the stock an “overweight” rating in a research note on Monday, November 25th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $55.00 price objective on shares of TG Therapeutics in a research note on Wednesday, January 15th. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $40.67.

TG Therapeutics Trading Down 0.0 %

Shares of TGTX opened at $33.36 on Friday. TG Therapeutics, Inc. has a one year low of $12.84 and a one year high of $36.84. The stock has a 50-day moving average price of $31.70 and a 200 day moving average price of $26.45. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59. The company has a market capitalization of $5.19 billion, a P/E ratio of -333.57 and a beta of 2.24.

TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings results on Monday, November 4th. The biopharmaceutical company reported $0.02 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.01). The firm had revenue of $83.90 million for the quarter, compared to analyst estimates of $81.68 million. TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The business’s revenue was down 49.4% on a year-over-year basis. During the same period in the prior year, the company posted $0.73 earnings per share. Sell-side analysts forecast that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

Insider Transactions at TG Therapeutics

In other news, CFO Sean A. Power sold 10,021 shares of TG Therapeutics stock in a transaction that occurred on Monday, January 6th. The shares were sold at an average price of $28.53, for a total value of $285,899.13. Following the transaction, the chief financial officer now directly owns 660,611 shares of the company’s stock, valued at $18,847,231.83. This trade represents a 1.49 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, Director Sagar Lonial sold 5,000 shares of the stock in a transaction dated Monday, November 11th. The stock was sold at an average price of $30.44, for a total value of $152,200.00. Following the completion of the sale, the director now directly owns 100,195 shares of the company’s stock, valued at approximately $3,049,935.80. This represents a 4.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 26,358 shares of company stock valued at $781,497. 10.50% of the stock is currently owned by corporate insiders.

TG Therapeutics Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.